United States Monoclonal Antibody Cancer Therapeutics Market

 

Regular Price: USD 3,950

Special Price USD 2,765

30% OFF

* Required Fields

Regular Price: USD 3,950

Special Price USD 2,765

PAY BY INVOICE

Be the first to review this product

Table of Contents

United States Monoclonal Antibody Cancer Therapeutics Market, Executive SummaryIntroduction to the US Monoclonal Antibody Cancer Therapeutics MarketIntroduction to the US Monoclonal Antibody Cancer Therapeutics MarketObjectives and PurposeReport Scope and SegmentationReport StructureCurrent TreatmentsAnalysis of Market Engineering ResearchAnalysis of Market Engineering ResearchDrivers Affecting the U.S. Monoclonal Antibody Cancer Therapeutics MarketRestraints Affecting the U.S. Monoclonal Antibody Cancer Therapeutics MarketAnalysis by Major SegmentForecasted RevenuesSegment Share Analysis Competitive AnalysisStrategies for SuccessUnited States Monoclonal Antibody Cancer Therapeutics Market, Market Engineering Research MethodologyResearch ScopeObjectives and PurposeReport Structure and Market SegmentationMarket Engineering Forecasting MethodologyOverviewStrategic Significance of the Market Engineering ForecastJudging Credibility and Accuracy of Market Engineering ForecastsForecast AssumptionsGlossary of TermsList of DefinitionsList of AcronymsUnited States Monoclonal Antibody Cancer Therapeutics Market, Industry ChallengesIdentification of Challenges Facing the Monoclonal Antibody Cancer Therapeutics MarketIdentification of Challenges Facing the Monoclonal Antibody Cancer Therapeutics MarketBuilding right alliance at the right timeIdentifying optimal drug synergies Demarcate the patient population that are susceptible to serious side-effects Standardizing tumor genotyping Demonstrating advantages over novel therapies Achieving economies of scale in manufacturing Optimizing humanized monoclonal antibody technology Demonstrating overall cost-savings for MAB therapy Unveiling of the human genome enlarges MAB targetsDemonstrate improvements in survival rates and quality of lifeUnited States Monoclonal Antibody Cancer Therapeutics Market, Total U.S. Monoclonal Antibody Cancer Therapeutics Market 1996-2006Market OverviewMarket OverviewScope/SegmentationScope/SegmentationMarket Engineering Research Measurement SystemMarket Engineering Research Measurement SystemMonoclonal Antibodies as Cancer TherapeuticsMonoclonal Antibodies as Cancer TherapeuticsAntigen SelectionHuman Anti-Mouse Antibodies (HAMA)Market DriversMarket RestraintsMarket Engineering Revenue Forecasts (1997-2006)Total RevenuesMonoclonal Antibodies for Solid Tumors Product RevenuesMonoclonal Antibodies for Anti-angiogenesis Product RevenuesMonoclonal Antibodies for Leukemias and Lymphomas Product RevenuesRevenue Trends by IndicationCompetitive StructureMarket Share AnalysisMarket Share Winner and WhyMarket Engineering Research for the U.S. Monoclonal Antibody Solid Tumor Therapeutics Market 1999-2006Market Overview and DefinitionsOverviewDefinitionScope/SegmentationMarket Engineering Research Measurement SystemMarket Engineering Research Measurement SystemSolid TumorsNear-term Products (Pivotal Trials)Epidermal Growth Factor Receptor (EGFR)Revenues Forecast – Monoclonal Antibody for Solid Tumor Therapeutic MarketImclone System’s Cetuximab (C225)Medarex’s MDX-447Market Engineering Revenue Forecasts (1999-2006)Competitive AnalysisProducts in DevelopmentHuman Epidermal Growth Factor Receptor-2 (HER-2)Market Engineering Revenue Forecasts (1999-2006)Herceptin RevenuesMDX-210 RevenuesCompetitive AnalysisCompetitive StructureCompetitive FactorsMonoclonal Antibodies for Ovarian CancerMarket Engineering Unit and Revenue Forecasts (1999-2006)Competitive AnalysisMarket Engineering Research for the U.S. Monoclonal Antibody Anti-Angiogenesis Market 1999-2006Market Overview and DefinitionsOverviewDefinitionScope/SegmentationMarket Engineering Research Measurement SystemMarket Engineering Research Measurement SystemMonoclonal Antibody Against Biological TargetsMarket Engineering Revenue Forecasts (2003-2006)Competitive AnalysisCompetitive StructureMarket Engineering Research for the U.S. Monoclonal Antibody Market for Leukemias and Lymphomas 1999-2006Market Overview and DefinitionsMarket Overview and DefinitionsScope and SegmentationScope and SegmentationMarket Engineering Research Measurement SystemMarket Engineering Research Measurement SystemMarket ForecastLeukemiaMarket Engineering Revenue Forecasts (1999-2006)Mylotarg RevenuesSMART M195 RevenuesCampath RevenuesLymphomaLymphomaNon-Hodgkin's Lymphoma (NHL)Rituxan RevenuesBexxar and Zevalin RevenuesPricing TrendsCompetitive StructureProducts in DevelopmentUnited States Monoclonal Antibody Cancer Therapeutics Market, Market Engineering StrategyMarket Engineering Strategic RecommendationsMarket Engineering Strategic RecommendationsCorporate Management Intellectual PropertyMarketing DepartmentResearch and DevelopmentMarket Engineering Awards for the Monoclonal Antibody Cancer Therapeutics Market Frost & Sullivan's 2001 Market Engineering AwardsFrost & Sullivan's 2001 Market Engineering AwardsMarket Engineering AwardsMarket Engineering AwardsAward Category: Market Engineering LeadershipAward Category: Product Line Strategy Award Category: Strategic Alliance Innovation United States Monoclonal Antibody Cancer Therapeutics Market, Database of Key Industry Participants Market ParticipantsMarket ParticipantsRelated CompaniesRelated CompaniesAssociationsAssociations




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 22-Nov-17

Region : North America

Release Date : 21-Nov-17

Region : North America

Release Date : 20-Nov-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.